KR20230119664A - 피부 홍반성 루푸스 및 전신성 홍반성 루푸스를 치료하는방법 - Google Patents

피부 홍반성 루푸스 및 전신성 홍반성 루푸스를 치료하는방법 Download PDF

Info

Publication number
KR20230119664A
KR20230119664A KR1020237022397A KR20237022397A KR20230119664A KR 20230119664 A KR20230119664 A KR 20230119664A KR 1020237022397 A KR1020237022397 A KR 1020237022397A KR 20237022397 A KR20237022397 A KR 20237022397A KR 20230119664 A KR20230119664 A KR 20230119664A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237022397A
Other languages
English (en)
Korean (ko)
Inventor
프랑수아 고드롤
히만슈 나이크
Original Assignee
바이오젠 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드 filed Critical 바이오젠 엠에이 인코포레이티드
Publication of KR20230119664A publication Critical patent/KR20230119664A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237022397A 2020-12-03 2021-12-03 피부 홍반성 루푸스 및 전신성 홍반성 루푸스를 치료하는방법 Pending KR20230119664A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121194P 2020-12-03 2020-12-03
US63/121,194 2020-12-03
PCT/US2021/061764 WO2022120144A1 (en) 2020-12-03 2021-12-03 Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
KR20230119664A true KR20230119664A (ko) 2023-08-16

Family

ID=79024222

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237022397A Pending KR20230119664A (ko) 2020-12-03 2021-12-03 피부 홍반성 루푸스 및 전신성 홍반성 루푸스를 치료하는방법

Country Status (15)

Country Link
US (1) US20240018246A1 (cg-RX-API-DMAC10.html)
EP (1) EP4255392A1 (cg-RX-API-DMAC10.html)
JP (2) JP2024501430A (cg-RX-API-DMAC10.html)
KR (1) KR20230119664A (cg-RX-API-DMAC10.html)
CN (1) CN116963716A (cg-RX-API-DMAC10.html)
AR (1) AR124247A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021391803A1 (cg-RX-API-DMAC10.html)
CA (1) CA3203971A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023001562A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023008272A2 (cg-RX-API-DMAC10.html)
IL (1) IL303279A (cg-RX-API-DMAC10.html)
MX (1) MX2023006474A (cg-RX-API-DMAC10.html)
PE (1) PE20231678A1 (cg-RX-API-DMAC10.html)
TW (1) TW202222829A (cg-RX-API-DMAC10.html)
WO (1) WO2022120144A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5007007B2 (ja) * 1999-11-15 2012-08-22 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞
BR122020023058B1 (pt) * 2012-12-10 2023-12-05 Biogen Ma Inc Ácido nucleico isolado ou ácidos nucleicos
CN109535254B (zh) * 2013-12-24 2022-06-24 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
EP3448425A1 (en) 2016-04-28 2019-03-06 Biogen MA Inc. Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Also Published As

Publication number Publication date
MX2023006474A (es) 2023-08-16
JP2026104953A (ja) 2026-06-25
AU2021391803A1 (en) 2023-07-06
TW202222829A (zh) 2022-06-16
AU2021391803A9 (en) 2024-09-26
IL303279A (en) 2023-07-01
CN116963716A (zh) 2023-10-27
WO2022120144A1 (en) 2022-06-09
US20240018246A1 (en) 2024-01-18
PE20231678A1 (es) 2023-10-19
JP2024501430A (ja) 2024-01-12
EP4255392A1 (en) 2023-10-11
AR124247A1 (es) 2023-03-01
CO2023008272A2 (es) 2023-09-29
CA3203971A1 (en) 2022-06-09
CL2023001562A1 (es) 2023-12-15

Similar Documents

Publication Publication Date Title
JP7736667B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
US20250289895A1 (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
JP6554155B2 (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
KR20210010518A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
CN107029234A (zh) 利用il‑17拮抗剂治疗牛皮癣的方法
KR20230170796A (ko) 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
CA3228708A1 (en) Treatment of atopic dermatitis
KR20240049351A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
US20240018246A1 (en) Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus
CN112839956A (zh) 安全有效治疗膝和/或髋疼痛的药物组合物
WO2017221174A1 (en) Methods of treating vitiligo using interleukin-17 (il-17) antibodies
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
EP4006053A1 (en) Method for treating autoimmune disease by il-17 antagonist
RU2801204C2 (ru) Способ лечения атопического дерматита посредством введения ингибитора ил-4r
CN117203232A (zh) 用抗il-13抗体治疗特应性皮炎的方法
EA053327B1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови
EA043069B1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230630

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241203

Comment text: Request for Examination of Application